- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Two of the world’s foremost cancer researchers announced Tuesday the creation of a new drug aimed at preventing the growth of an array of cancers, the Toronto Star reported.
Two of the world’s foremost cancer researchers announced Tuesday the creation of a new drug aimed at preventing the growth of an array of cancers, the Toronto Star reported.
As quoted in the market news:
Tak Mak, director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, and Dr. Dennis Slamon, of the University of California, Los Angeles, are part of the 100-person team that developed the drug, which has been tested on human ovarian, breast, pancreas, lung and colon cancer in mice.
The researchers are calling the drug a “sharpshooter” for its ability to target a specific enzyme, rather than take a “one-size fits all” approach, Slamon explained to reporters at a Toronto news conference.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.